Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
19 Aug 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
12 Aug 24
8-K
Other Events
15 Jul 24
424B3
Prospectus supplement
24 Jun 24
EFFECT
Notice of effectiveness
24 Jun 24
S-3
Shelf registration
14 Jun 24
8-K
Entry into a Material Definitive Agreement
5 Jun 24
8-K
Coya Therapeutics Announces $5 Million Strategic
20 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
9 May 24
8-K
Departure of Directors or Certain Officers
8 May 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
19 Mar 24
8-K
Other Events
19 Jan 24
424B3
Prospectus supplement
16 Jan 24
EFFECT
Notice of effectiveness
16 Jan 24
CORRESP
Correspondence with SEC
10 Jan 24
UPLOAD
Letter from SEC
9 Jan 24
S-3
Shelf registration
4 Jan 24
D
$26.48 mm in equity / options / securities to be acquired, sold $26.48 mm, 122 investors
20 Dec 23
8-K
Departure of Directors or Certain Officers
20 Dec 23
8-K
Entry into a Material Definitive Agreement
6 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
8 Nov 23
8-K
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya’s Board of Directors
21 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
8 Aug 23
8-K
Departure of Directors or Certain Officers
14 Jul 23
8-K
Departure of Directors or Certain Officers
10 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
8-K
Regulation FD Disclosure
12 Jun 23
8-K
Other Events
23 May 23
DEFA14A
Additional proxy soliciting materials
19 May 23
ARS
2022 FY
Annual report to shareholders
19 May 23
DEF 14A
Definitive proxy
19 May 23
8-K
Regulation FD Disclosure
16 May 23
Latest ownership filings
3
Arun Swaminathan
20 Aug 24
4
DAVID S SNYDER
5 Jun 24
4
Howard Berman
5 Jun 24
4
Fred Grossman
5 Jun 24
4
Ann Lee
5 Mar 24
SC 13G/A
GREENLIGHT CAPITAL INC
14 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
4
Fred Grossman
2 Feb 24
4
DAVID S SNYDER
2 Feb 24
4
Howard Berman
2 Feb 24
4
Dieter Weinand
19 Jan 24
4
Hideki Garren
19 Jan 24
4
DOV A MD GOLDSTEIN
19 Jan 24
4
Ann Lee
19 Jan 24
4
Anabella Villalobos
19 Jan 24
4
WILBUR L ROSS JR
4 Jan 24
3
WILBUR L ROSS JR
29 Dec 23
SC 13G
GREENLIGHT CAPITAL INC
12 Dec 23
4
Dieter Weinand
21 Aug 23
3
Dieter Weinand
21 Aug 23
4
Fred Grossman
19 Jul 23
3
Fred Grossman
19 Jul 23
4
Howard Berman
1 Mar 23
4
Adrian Hepner
1 Mar 23
4
DAVID S SNYDER
1 Mar 23
SC 13G/A
Berman Howard
14 Feb 23
SC 13G
Berman Howard
14 Feb 23
4/A
Howard Berman
17 Jan 23
SC 13G
HIRSCHMAN ORIN
5 Jan 23
4
Howard Berman
4 Jan 23
4
Ann Lee
4 Jan 23
4
Adrian Hepner
4 Jan 23
4
Hideki Garren
4 Jan 23
4
DAVID S SNYDER
4 Jan 23
4
Anabella Villalobos
4 Jan 23
4
DOV A MD GOLDSTEIN
4 Jan 23
3
Initial statement of insider ownership
28 Dec 22
3
DAVID S SNYDER
28 Dec 22
3
Ann Lee
28 Dec 22
3
Hideki Garren
28 Dec 22